Articles

Capecitabine and folic acid: A lethal combination?

BJMO - volume 16, issue 2, march 2022

D. Naudts MD, L-A. Teuwen MD, J. Van Boven , H. Prenen MD, PhD, T. Vandamme MD, PhD, B. Van Overberghe MD, K. Forceville MD, M. Peeters MD, PhD

SUMMARY

5-Fluorouracil (5-FU) and its prodrug capecitabine are widely used and generally well-tolerated chemotherapeutic agents. Although leucovorin, a derivative of folic acid, is routinely used to potentiate the effect of 5-FU, there seems to be little to no awareness about a similar interplay between capecitabine and folic acid, a commonly used supplement. This study presents a case in which a high concentration of folic acid led to fatal capecitabine-related toxicity, with the aim to raise awareness on the interaction between folic acid supplementation and 5-FU/capecitabine treatment toxicity.

(BELG J MED ONCOL 2022;16(2):74–8)

Read more

Highlights in digestive oncology

BJMO - volume 15, issue 8, december 2021

H. Dedecker MD, L-A. Teuwen MD, T. Vandamme MD, PhD, H. Prenen MD, PhD, M. Peeters MD, PhD

The 2021 edition of ESMO was held virtually between the 16th and 21st of September 2021. The main goal of this overview is to highlight the most striking abstracts in the field of digestive oncology for daily clinical practice. First, the upper gastro-intestinal tract tumours will be discussed, followed by an overview of the congress highlights related to cancers of the lower gastro-intestinal tract.

(BELG J MED ONCOL 2021;15(5):415–20)

Read more

Highlights in digestive oncology

BJMO - volume 14, issue 8, december 2020

L-A. Teuwen MD, M. Peeters MD, PhD, T. Vandamme MD, PhD, H. Prenen MD, PhD

The annual ESMO meeting was held virtually between 19th and 21st September 2020 and covered many interesting abstracts in the field of digestive oncology. In this overview, our main aim was to highlight the data that are most relevant for daily clinical practice. This year, we will discuss the results according to the traditional division in upper and lower gastro-intestinal tract tumours.

Read more

Systemic treatment for basal cell carcinoma of the skin

BJMO - volume 9, issue 7, december 2015

L. Dirix MD, L-A. Teuwen MD, A. Rutten MD

(BELG J MED ONCOL 2015;9(7):265–71)

Read more
X